| Автор | Moreau, Th |
| Автор | Coles, A |
| Автор | Wing, M |
| Автор | Thorpe, J |
| Автор | Miller, D |
| Автор | Moseley, I |
| Автор | Issacs, J |
| Автор | Hale, G |
| Автор | Clayton, D |
| Автор | Scolding, N |
| Автор | Waldmann, H |
| Автор | Compston, A |
| Дата выпуска | 1996 |
| dc.description | In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-1H which targets the CD52 antigen present on lymphocytes and monocytes. There was a substantial reduction in disease activity as measured by gadoliunium-enhancing lesions on MRI. Encouraged by this result a further seven patients have been treated with CAMPATH-1H; four also received anti-CD4 antibody. Lymphopaenia developed rapidly and was sustained for at least one year. In 12 patients, the first infusion of antibody was characterised by significant exacerbation or re-awakening of pre-existing symptoms lasting several hours. These clinical effects of antibody treatment correlated with increased levels of circulating cytokines. Peak levels of tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) occurred at 2 h whereas the rise in interleukin-6 (IL-6) was significantly delayed and peaked at 4 h after starting antibody treatment The neurological symptoms could not be attributed directly to pyrexia and were not provoked (in one patient) by an artificial rise in temperature. In the remaining two patients, a single pre-treatment with intravenous methylprednisolone (500 mg) prevented both the transient increase in neurological symptoms and the cytokine release. Our results suggest that soluble immune mediators contribute to symptom production in multiple sclerosis by directly or indirectly blocking conduction through partially demyelinated pathways. |
| Издатель | SAGE Publications |
| Тема | multiple sclerosis |
| Тема | campath-1h |
| Тема | cytokines |
| Тема | lymphocytes |
| Тема | symptoms |
| Тема | MRI |
| Название | CAMPATH-1H in multiple sclerosis |
| Тип | Journal Article |
| DOI | 10.1177/135245859600100616 |
| Electronic ISSN | 1477-0970 |
| Print ISSN | 1352-4585 |
| Журнал | Multiple Sclerosis |
| Том | 1 |
| Первая страница | 357 |
| Последняя страница | 365 |
| Аффилиация | Moreau, Th, University of Cambridge Neurology unit, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Coles, A, University of Cambridge Neurology unit, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Wing, M, Molecular Immunopathology Unit, MRC Centre, Hills Road, Cambridge CB2 2QH |
| Аффилиация | Thorpe, J, Institute of Neurology, London WC1 |
| Аффилиация | Miller, D, Institute of Neurology, London WC1 |
| Аффилиация | Moseley, I, National Hospital, London WC12 |
| Аффилиация | Issacs, J, Division of Immunology, Department of Pathology, University of Cambridge, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Hale, G, Division of Immunology, Department of Pathology, University of Cambridge, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Clayton, D, Division of Immunology, Department of Pathology, University of Cambridge, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Scolding, N, University of Cambridge Neurology unit, Addenbrookeʼs Hospital, Hills Road, Cambridge CB2 2QQ |
| Аффилиация | Waldmann, H, Sir William Dunn School of Pathology, South Parks Road, Oxford, OX1 2QQ |
| Аффилиация | Compston, A, MRC Cambridge Centre for Brain Repair, University Forvie Site, Robinson Way, Cambridge CB2 2PY, USA |
| Выпуск | 6 |
| Библиографическая ссылка | 1 Ebers GC. (1994) Science and Practice. The treatment of multiple sclerosis. Lancet 343: 275–279. |
| Библиографическая ссылка | 2 Ffrench-Constant C. (1994) The pathogenesis of multiple sclerosis. Lancet 343: 271–275. |
| Библиографическая ссылка | 3 Raine CS. (1991) Multiple sclerosis; a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 17: 265–274. |
| Библиографическая ссылка | 4 Hafler DA et al. (1988) Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis, immunosuppressive effect and human anti-mouse responses. J Immunol 141: 131–138. |
| Библиографическая ссылка | 5 Lindsey JW et al. (1994) Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 44: 413–419. |
| Библиографическая ссылка | 6 Weinshenker BG et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41: 1047–1052. |
| Библиографическая ссылка | 7 Riechmann L et al. (1988) Reshaping human antibodies for therapy. Nature 332: 323–327. |
| Библиографическая ссылка | 8 Katz D et al. (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34: 661–669. |
| Библиографическая ссылка | 9 Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 54: 683–688. |
| Библиографическая ссылка | 10 Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis; guidelines for research protocols. Ann Neurol 13: 227–231. |
| Библиографическая ссылка | 11 Moreau T et al. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225–237. |
| Библиографическая ссылка | 12 Moreau T et al. (1994) Preliminary evidence from gadolinium enhanced magnetic resonance imaging for reduction in disease activity following lymphocyte depletion in multiple sclerosis. Lancet 344: 298–301. |
| Библиографическая ссылка | 13 Uhthoff W. (1989) Untersuchem über die bei der multiplen Herdskloerose vorkommenden Augenstörungen. Achiv für Psychiatrie und Nervenkrankheiten 21: 55–116. |
| Библиографическая ссылка | 14 Nauta JJP et al. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel groups and cross-over designs. J Neurol Sci 122: 6–14. |
| Библиографическая ссылка | 15 McDonald WI, Barnes D. (1989) Lessons from magnetic resonance imaging in multiple sclerosis. Trends Neurosci 12: 376–379. |
| Библиографическая ссылка | 16 Kermode AG et al. (1990) Breakdown of the blood brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 113: 1477–1489. |
| Библиографическая ссылка | 17 Youl BD et al. (1991) The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and eletrophysiological deficits. Brain 114: 2437–2450. |
| Библиографическая ссылка | 18 Miller DH, Barkhoff, Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting new disease activity in multiple sclerosis. Brain 116: 1077–1094. |
| Библиографическая ссылка | 19 Hale G et al. (1990) The CAMPATH-1H antigen (CDW52). Tissue Antigens 35: 1–10. |
| Библиографическая ссылка | 20 Waldmann H et al. (1984) Elimination of grat-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1H). Lancet ii: 483–485. |
| Библиографическая ссылка | 21 Isaacs JD et al. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748–752. |
| Библиографическая ссылка | 22 Lockwood CM et al. (1993) Long-term remission of intreatable systemic vasculitis with monoclonal antibody therapy. Lancet 341: 1620–1622. |
| Библиографическая ссылка | 23 Hale G et al. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet ii: 1394–1399. |
| Библиографическая ссылка | 24 Racadot E et al. (1993) Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. Autoimmunity 6: 771–786. |
| Библиографическая ссылка | 25 Peces R et al. (1992) High-dose of methyl-prednisolone inhibits the OKT3-induced cytokine-related syndrome. Nephron 63: 1–4. |
| Библиографическая ссылка | 26 Marx Jean. (1995) How the glucocorticoids suppress immunity. Science 270: 232–233. |
| Библиографическая ссылка | 27 Ellison MD et al. (1991) Appearance of cytokine-associated central nervous system myelin coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 33: 245–251. |
